clear
Saturday October 21st, 2017 12:52AM

FDA advisers endorse gene therapy to treat form of blindness

By The Associated Press
Related Articles
  Contact Editor

SILVER SPRING, Md. (AP) — A potentially groundbreaking treatment for a rare form of blindness moved one step closer to U.S. approval Thursday, as federal health advisers endorsed the experimental gene therapy for patients with an inherited condition that gradually destroys eyesight.

The panel experts to the Food and Drug Administration voted unanimously in favor of Spark Therapeutics' injectable therapy, which aims to improve vision by replacing a defective gene needed to process light.

The vote amounts to a recommendation to approve the therapy. The FDA has until mid-January to make its decision and does not have to follow the panel's recommendation, though it often does.

If approved, Luxturna would be the first gene therapy in the U.S. for an inherited disease and the first in which a corrective gene is given directly to patients. While the therapy from Spark Therapeutics targets a small group of patients — about 2,000 in the U.S. — experts say it could pave the way for other genetic treatments for a variety of inherited conditions.

Panelists debated several specifics of the treatment, splitting on whether to require a minimum age for treatment; the company says the drug is intended for those 3 years and older. Panelists concluded that the science behind the drug — based on research from the Children's Hospital of Philadelphia — was remarkably strong with few serious side effects.

Several patients attended the meeting to urge panelists to support the drug, relating experiences of seeing snow, stars and the moon for the first time. In most cases, the patients' travel expenses were paid for by the drug's developer.

Katelyn Corey, 24, described her life before the treatment as "a black and white film."

"Within days of the first treatment I could see vibrant colors again," Corey said. "I could see the clock tower of Philadelphia City Hall at night when mere days before I thought it was the moon."

Ashley Carper, a mother of two children with the disorder, said treatment has allowed her 11-year-old son Cole to read large-print books and write his own homework. Previously he could only read with Braille. Cole said the improvements extend beyond schoolwork.

"I can stay out later when my friends are outside playing and now I feel like part of the group," he said. "My vision is not perfect, but what I do have is still really important to me."

Researchers tested the treatment by recording patients' ability to complete an obstacle course at varying levels of light, simulating real-world conditions like navigating a dark stairwell. A hallmark of the inherited disorder is difficulty seeing at night. Patients with the mutation generally start losing their sight before age 18, almost always progressing to total blindness.

One year after treatment 18 out of 20 patients who received the injection showed the maximum improvement in completing the obstacle course, and 13 completed the task at the lowest level of light. None of the patients in a comparison group did.

Doctors deliver the therapy with an injection in each eye that inserts a replacement gene into the retina via a modified virus.

Philadelphia-based Spark Therapeutics hopes to use its technology to treat other retinal disorders, including one called choroideremia, which affects about three times as many people as the condition currently under FDA review. The company is also investigating therapies to treat the blood disorder hemophilia and diseases of the nervous system.

As a potential breakthrough therapy for a rare disease, much of the discussion around Luxturna has focused on its cost. Drugmakers often price similar drugs at $250,000 or more. Spark has not given an estimated cost, which companies usually announce only after approval. But the company's stock ticker symbol "ONCE" reinforces the company's hope that this will be a one-time treatment — and expense.

"It is the aspiration," Spark Therapeutics CEO Jeff Marrazzo told The Associated Press prior to the meeting.

Pharmaceutical analyst Michael Yee estimates the drug will be priced between $350,000 and $450,000 per injection. He expects sales of $40 million to $50 million in 2018, growing to as much as $100 million in 2019.

___

AP Medical Writer Marilynn Marchione contributed to this story.

  • Associated Categories: U.S. News, Associated Press (AP), AP National News, Top U.S. News short headlines, AP Health, AP Business, AP Business - Corporate News
© Copyright 2017 AccessWDUN.com
All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
FDA advisers endorse gene therapy to treat form of blindness
U.S. health advisers are deciding whether to recommend approval of an experimental treatment for improving vision in patients with a rare form of blindness.
4:38PM ( 16 minutes ago )
Police: Texas Tech student questioned hours before shooting
Authorities say Lubbock police officers questioned a Texas Tech University student about a stolen gun hours before he shot and killed a campus police officer
4:33PM ( 20 minutes ago )
Plumbing company owner charged in 3 Louisiana slayings
A plumbing company owner is accused of killing three men and shooting a fourth in a string of attacks that began in July in a rural area north of Baton Rouge
4:33PM ( 20 minutes ago )
U.S. News
Ryan blasts states that send billions to federal government
The top House Republican slams high-tax states that deliver billions to the federal government as he faces a backlash from rank-and-file GOP lawmakers over a sweeping tax-cutting proposal.
4:37PM ( 17 minutes ago )
Congress OKs expanded protections for federal whistleblowers
Congress has voted to boost the protection of federal whistleblowers from retaliation, part of a bid to uncover bad behavior at the Department of Veterans Affairs and other agencies
4:26PM ( 27 minutes ago )
Trump to bash Iran on non-nuke issues in decertifying deal
President Donald Trump plans to deliver a broad and harsh critique of Iranian behavior in a speech this week declaring that the landmark Iran nuclear deal is not in America's national security interests
4:22PM ( 31 minutes ago )
Associated Press (AP)
Boy's body found after 3 adults slain; manhunt underway
Authorities say a 7-year-old boy was shot dead and his body apparently hidden in a home where three adults were found fatally shot and a fourth was stabbed
4:12PM ( 41 minutes ago )
Dangerous sound? What Americans heard in Cuba attacks
The Associated Press has obtained a recording of what some U.S. embassy workers heard in Havana as they were attacked by what investigators initially believed was a sonic weapon
4:10PM ( 44 minutes ago )
Trump lashes out at Puerto Rico as House weighs aid package
President Donald Trump is lashing out at hurricane-devastated Puerto Rico, insisting that federal help will be limited and blaming the U.S. territory for its financial struggles
4:06PM ( 47 minutes ago )
AP National News
Russia-backed Facebook page colored with hot-button phrases
What does Russia-sponsored political influence look like on Facebook? An Associated Press analysis of the content on a now-shuttered Facebook page called 'Being Patriotic' shows it's colored with words like 'illegal,' 'country' and 'American'
3:53PM ( 1 hour ago )
US stocks mixed as retailers slump and tech companies rise
US stocks are mixed as a poor forecast from J. Jill weighs on retailers, but technology and industrial companies make gains
3:50PM ( 1 hour ago )
Louisiana man accused of killing 3 in string of attacks
A plumbing company owner is accused of killing three men and shooting a fourth in a string of attacks that began in July in a rural area north of Baton Rouge
3:09PM ( 1 hour ago )
AP Business
APNewsBreak: Border Patrol tests camera-toting balloon
APNewsBreak: The US Border Patrol is considering a smaller version of tethered balloons loaded with cameras that can be quickly moved to spot illegal activity, part of an effort to see if more eyes in the sky translate to fewer illegal crossings
2:29PM ( 2 hours ago )
In JP Morgan's 3Q, consumer banking offsets drop in trading
JPMorgan Chase beats 3Q profit expectations, helped by consumer banking division
1:09PM ( 3 hours ago )
Facebook's Sandberg favors release of Russia-linked ads
Facebook's chief operating officer, Sheryl Sandberg, says the ads linked to Russia trying to influence the US election should 'absolutely' be released to the public.
12:52PM ( 4 hours ago )
AP Business - Corporate News
Police: Texas Tech student questioned hours before shooting
Authorities say Lubbock police officers questioned a Texas Tech University student about a stolen gun hours before he shot and killed a campus police officer
4:33PM ( 20 minutes ago )
Plumbing company owner charged in 3 Louisiana slayings
A plumbing company owner is accused of killing three men and shooting a fourth in a string of attacks that began in July in a rural area north of Baton Rouge
4:33PM ( 21 minutes ago )
Searchers look for bodies in California's charred ruins
Search teams begin grim work of finding more wildfire victims
4:29PM ( 25 minutes ago )
The Latest: Security guard killed at concert mourned as hero
A U.S. official says the Mandalay Bay hotel casino didn't notify police that gunshots had been fired inside the tower until after a gunman opened fire on the crowd outside at a country music festival
4:25PM ( 29 minutes ago )
Official says Vegas hotel didn't immediately report gunfire
A federal official says Mandalay Bay hotel officials didn't notify police about a shooting in a hallway inside the high-rise until after Stephen Paddock opened fire on the crowd outside at a country music festival
4:25PM ( 29 minutes ago )